Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $75.83
  • 50 Day Moving Average: $77.03
  • 200 Day Moving Average: $83.21
  • 52-Week Range: $72.21 - $110.77
  • Trailing P/E Ratio: 6.66
  • Foreward P/E Ratio: 6.89
  • P/E Growth: -27.57
  • Market Cap: $100.07B
  • Outstanding Shares: 1,319,658,000
  • Beta: 1.1
  • Net Margins: 50.50%
  • Return on Equity: 106.75%
  • Return on Assets: 35.82%
  • Debt-to-Equity Ratio: 1.36%
  • Current Ratio: 1.76%
  • Quick Ratio: 1.58%
Additional Links:
Companies Related to Gilead Sciences:

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 9 Hold Ratings, 18 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $103.44 (36.42% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
DateFirmActionRatingPrice TargetDetails
10/26/2016William BlairReiterated RatingOutperformView Rating Details
10/25/2016Jefferies GroupBoost Price TargetBuy$93.00 -> $95.00View Rating Details
10/23/2016Cowen and CompanySet Price TargetBuy$120.00View Rating Details
10/22/2016Piper Jaffray Cos.Reiterated RatingOverweightView Rating Details
10/18/2016Robert W. BairdReiterated RatingOutperform$122.00 -> $100.00View Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00View Rating Details
10/3/2016RBC Capital MarketsReiterated RatingBuy$105.00 -> $95.00View Rating Details
10/3/2016Royal Bank Of CanadaBoost Price TargetOutperform$95.00 -> $105.00View Rating Details
9/30/2016Leerink SwannReiterated RatingOutperform$112.00View Rating Details
9/27/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$80.00View Rating Details
9/25/2016Bank of America Corp.Reiterated RatingNeutral$100.00View Rating Details
9/23/2016GabelliReiterated RatingBuyView Rating Details
9/22/2016Berenberg BankInitiated CoverageBuyView Rating Details
9/14/2016Credit Suisse Group AGLower Price TargetOutperform$115.00 -> $95.00View Rating Details
9/6/2016Morgan StanleySet Price TargetHold$100.00View Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details
7/28/2016Barclays PLCReiterated RatingOverweightView Rating Details
7/27/2016Maxim GroupSet Price TargetHold$88.55View Rating Details
7/27/2016BMO Capital MarketsReiterated RatingMarket Perform$97.00 -> $98.00View Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
7/26/2016Needham & Company LLCDowngradeBuy -> Hold$84.60 -> $88.55View Rating Details
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details
5/14/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details
4/10/2016MizuhoReiterated RatingBuy$130.00View Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details
8/7/2015Stifel NicolausDowngradeHoldView Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details
10/31/2014Edward JonesInitiated CoverageHoldView Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016Q316$2.87$7.47 billionListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
Current Year EPS Consensus Estimate: $11.42 EPS
Next Year EPS Consensus Estimate: $11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.77$3.04$2.87
Q4 20163$2.76$2.98$2.84
(Data provided by Zacks Investment Research)


Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.48%
Payout Ratio:16.56% (Based on Trailing 12 Months of Earnings)
16.46% (Based on Current Year Consensus EPS Estimate)
17.09% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 78.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline logoStocks on Trader's Radar: Gilead Sciences Inc. (GILD), Bristol-Myers Squibb Company (BMY), Symantec Corporation ... - iStreetWire (NASDAQ:GILD) - October 27 at 5:17 PM
News IconShould You Buy Gilead Stock Now? : Gilead Sciences, Inc (GILD) - Amigobulls (NASDAQ:GILD) - October 27 at 5:17 PM logoBetter Buy: Gilead Sciences Inc. vs. Johnson & Johnson (NASDAQ:GILD) - October 27 at 10:48 AM
News Icon2 Sizzling Hot Biotechnology Stocks: ZIOPHARM Oncology, Inc. (ZIOP), Gilead Sciences Inc. (GILD) - The Independent Republic (NASDAQ:GILD) - October 27 at 9:55 AM logoDMG MORI increases order intake by 12% in the third quarter Initial sucess with realignment (NASDAQ:GILD) - October 27 at 9:55 AM
News IconTime To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Corbus Pharmaceuticals Holdings, Inc ... - The Voice Registrar (NASDAQ:GILD) - October 26 at 5:18 PM logoGilead Sciences (GILD) Q3 Earnings: Stock to Disappoint? - Yahoo Finance (NASDAQ:GILD) - October 26 at 5:18 PM logo3 Key Questions for Gilead Sciences, Inc. in Q3 (NASDAQ:GILD) - October 26 at 8:37 AM logoStocks in the Spotlight: Gilead Sciences Inc. (GILD), Office Depot, Inc. (ODP), Starbucks Corporation (SBUX) - iStreetWire (NASDAQ:GILD) - October 26 at 8:23 AM logoAnalyst Update: Clovis Oncology Inc, Calithera Biosciences Inc, and Gilead Sciences, Inc. - Schaeffers Research (blog) (NASDAQ:GILD) - October 26 at 8:23 AM
News IconA look at the intrinsic value of Gilead Sciences Inc (GILD) - Simply Wall St (NASDAQ:GILD) - October 26 at 8:23 AM
News IconLourd Capital LLC invests in Gilead Sciences Inc. (GILD) Shares - DailyQuint (NASDAQ:GILD) - October 26 at 8:23 AM logoWilliam Blair Positive on Gilead Sciences, Inc. (GILD) Following Data Releases - Smarter Analyst (NASDAQ:GILD) - October 26 at 8:23 AM
News IconUpdated Analyst's outlook: Gilead Sciences, Inc. (NASDAQ:GILD) , Edwards Lifesciences Corporation (NYSE (NASDAQ:GILD) - October 25 at 5:16 PM
News IconGryphon International Investment Corp Lowers stake in Gilead Sciences (GILD) (NASDAQ:GILD) - October 25 at 5:16 PM logoWilliam Blair Positive on Gilead Sciences, Inc. (GILD) Following Data Releases (NASDAQ:GILD) - October 25 at 5:16 PM
News IconGilead Sciences Inc. (GILD) Rating Reiterated by Piper Jaffray Cos (NASDAQ:GILD) - October 25 at 5:16 PM logoCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Presents Results from ... (NASDAQ:GILD) - October 25 at 10:09 AM logoCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Presents ... - Smarter Analyst (NASDAQ:GILD) - October 24 at 5:02 PM
News IconScorching Hot Biotech Stocks Tape: Gilead Sciences Inc. (GILD), Merrimack Pharmaceuticals, Inc. (MACK) - The Independent Republic (NASDAQ:GILD) - October 24 at 5:02 PM logoGilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7 (NASDAQ:GILD) - October 24 at 5:02 PM logoQuarterly Accrued Expenses For Gilead Sciences, Inc. (NASDAQ:GILD) At $5447 Millions (NASDAQ:GILD) - October 24 at 10:29 AM logo6:25 am Gilead Sciences announces two-year data from a Phase 3 study and 48-week data from two Phase 3b studies evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected patients from regimens containing Truvad (NASDAQ:GILD) - October 24 at 10:29 AM logoGilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens (NASDAQ:GILD) - October 24 at 10:29 AM logoGilead's Hep C Phase 3 Shows Good Outcomes (GILD) (NASDAQ:GILD) - October 22 at 9:28 AM
News IconGilead Sciences Inc. (NASDAQ:GILD) Insider Activities Are in the Air (NASDAQ:GILD) - October 22 at 9:28 AM logoCowen Analyst: Gilead Sciences, Inc. (GILD) Is Undervalued As GS-4997 Moves to Phase III in NASH (NASDAQ:GILD) - October 22 at 9:28 AM
News Icon2 Stocks Attracting Analyst Attention: Gilead Sciences Inc. (NASDAQ:GILD), United Continental Holdings, Inc. (NYSE ... - The Voice Registrar (NASDAQ:GILD) - October 21 at 5:21 PM
News IconBiotech Stocks Worth Chasing: Galena Biopharma, Inc. (GALE), Gilead Sciences Inc. (GILD) - The Independent Republic (NASDAQ:GILD) - October 21 at 5:21 PM logoCowen Analyst: Gilead Sciences, Inc. (GILD) Is Undervalued As GS-4997 Moves to Phase III in NASH - Smarter Analyst (NASDAQ:GILD) - October 21 at 5:21 PM logoPiper Jaffray Shares Two Cents on Gilead Sciences, Inc. (GILD) Clinical Updates (NASDAQ:GILD) - October 21 at 8:22 AM logoCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces Clinical Updates - Smarter Analyst (NASDAQ:GILD) - October 20 at 5:18 PM
News IconGilead Sciences, Inc.: Why GILD Stock Could Surge 86% - Profit Confidential (NASDAQ:GILD) - October 20 at 5:18 PM logoGilead Sciences: Is the Bar Set Low Enough for a Beat? (NASDAQ:GILD) - October 20 at 5:17 PM logoNotable Thursday Option Activity: GILD, MDLZ, TRV (NASDAQ:GILD) - October 20 at 3:10 PM logoGilead Sciences Announces Results From Four Phase 3 POLARIS Studies (NASDAQ:GILD) - October 20 at 10:43 AM
News IconGilead Sciences, Inc.: Why GILD Stock Could Surge 86% (NASDAQ:GILD) - October 20 at 10:43 AM logoGilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients (NASDAQ:GILD) - October 20 at 10:43 AM logoGilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) (NASDAQ:GILD) - October 20 at 10:43 AM
News IconBrokerages Set Gilead Sciences Inc. (GILD) Target Price at $103.28 (NASDAQ:GILD) - October 19 at 5:36 PM
News IconTop Gainers of the Day: Gilead Sciences Inc. (NASDAQ:GILD) from Biotechnology (NASDAQ:GILD) - October 19 at 5:36 PM
News IconGilead Sciences Inc. (GILD) Given Consensus Rating of "Buy" by Brokerages (NASDAQ:GILD) - October 19 at 5:36 PM logo41 Billion Reasons Why Gilead Sciences Might Need New Management (NASDAQ:GILD) - October 19 at 3:57 PM logoStocks In Action: Starbucks Corporation (SBUX), Gilead Sciences Inc. (GILD), Square, Inc. (SQ) - iStreetWire (NASDAQ:GILD) - October 19 at 10:07 AM
News IconScorching Hot Biotech Stocks Tape: Mast Therapeutics, Inc. (MSTX), Gilead Sciences Inc. (GILD) - The Independent Republic (NASDAQ:GILD) - October 18 at 5:08 PM logoBetter Buy: Biogen Inc. vs. Gilead Sciences, Inc. -- The Motley Fool - Motley Fool (NASDAQ:GILD) - October 18 at 5:08 PM logoStocks Intraday Alert: Fifth Third Bancorp (FITB), Gilead Sciences Inc. (GILD), Halliburton Company (HAL) - iStreetWire (NASDAQ:GILD) - October 18 at 5:08 PM
News IconBiotech Stocks Worth Chasing: Achillion Pharmaceuticals, Inc ... - The Independent Republic (NASDAQ:GILD) - October 18 at 5:08 PM logoGilead Sciences Inc (GILD) Price Target Trimmed At Baird On Prescriptions Decline - TCC (NASDAQ:GILD) - October 18 at 5:07 PM logoGilead Sciences (GILD) Stock Up, Jefferies: Buy on Pre-Election Weakness (NASDAQ:GILD) - October 18 at 5:07 PM


Gilead Sciences (NASDAQ:GILD) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff